Merus N.V.
UTRECHT, The Netherlands and CAMBRIDGE, Mass., March 08, 2021 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., Chief Executive Officer, will participate in a fireside chat at the 33rd Annual Roth Conference on Monday, March 15 at 2:00 p.m. ET.
The live webcast of the presentation will be available on the Investors page of the Company's website, https://ir.merus.nl. An archived presentation will be available on the Merus website for a limited time.
About Merus
Merus is a clinical-stage oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, http://www.merus.nl and https://twitter.com/MerusNV.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Fynske Bank A/S4.7.2025 19:50:00 CEST | Pressemeddelelse
Fynske Bank og Nordfyns Bank indgår ny aftale om fusion med forhøjet fusionsvederlag
Nordfyns Bank A/S4.7.2025 19:50:00 CEST | Pressemeddelelse
Fynske Bank og Nordfyns Bank indgår ny aftale om fusion med forhøjet fusionsvederlag
Schweiter Technologies4.7.2025 18:00:00 CEST | Press release
INVITATION TO THE MEDIA & ANALYST WEBCAST
Siili Solutions Oyj4.7.2025 17:30:00 CEST | Press release
Siili Solutions Plc: Share Repurchase 4.7.2025
Tryg A/S4.7.2025 16:23:51 CEST | Press release
Correction: Consensus estimates on Tryg A/S
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom